SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MARCHESI, Elena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.477
EU - Europa 427
AS - Asia 311
OC - Oceania 2
SA - Sud America 2
AF - Africa 1
Totale 2.220
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.472
CN - Cina 126
IT - Italia 125
SG - Singapore 125
PL - Polonia 101
UA - Ucraina 54
DE - Germania 46
GB - Regno Unito 40
ID - Indonesia 26
SE - Svezia 22
TR - Turchia 22
FI - Finlandia 19
BE - Belgio 9
VN - Vietnam 7
CA - Canada 5
IN - India 4
NL - Olanda 4
FR - Francia 3
LT - Lituania 3
AU - Australia 2
CL - Cile 2
NO - Norvegia 1
PH - Filippine 1
ZA - Sudafrica 1
Totale 2.220
Salva come PNG Salva come JPEG
Città #
Fairfield 194
Woodbridge 154
Chandler 121
Ann Arbor 113
Santa Clara 105
Singapore 100
Warsaw 99
Houston 96
Ashburn 82
Cambridge 74
Seattle 71
Jacksonville 66
Ferrara 60
Wilmington 59
Beijing 35
Princeton 27
Jakarta 26
Shanghai 24
Izmir 22
Nanjing 20
Milan 16
San Diego 14
Boardman 12
New York 12
Bologna 11
Brussels 9
Frankfurt am Main 9
Helsinki 9
London 8
Munich 8
Dong Ket 7
Auburn Hills 6
Los Angeles 6
Shenyang 6
Tianjin 6
Falls Church 5
Ferrara di Monte Baldo 5
Hebei 5
Parma 5
Bremen 4
Jiaxing 4
Leiden 4
Fort Worth 3
Guangzhou 3
Weihai 3
Argenta 2
Cesano Maderno 2
Changsha 2
Imola 2
Kolkata 2
Kunming 2
Lawrenceville 2
Mountain View 2
Nanchang 2
Orange 2
Ottawa 2
Polska 2
Redwood City 2
Rome 2
Stockholm 2
Toronto 2
Washington 2
Baguio City 1
Bangalore 1
Bra 1
Carlsbad 1
Chatsworth 1
Chicago 1
Clearwater 1
Codigoro 1
Falkenstein 1
Hangzhou 1
Hunters Hill 1
Indiana 1
Jinan 1
Kilburn 1
Lappeenranta 1
Livorno 1
Maple Ridge 1
Ningbo 1
Norwalk 1
Novara 1
Philadelphia 1
Phoenix 1
Prescot 1
Pune 1
Redmond 1
Rueil-Malmaison 1
San Giorgio di Piano 1
San Mateo 1
Southwark 1
Stavanger 1
Verona 1
Zhengzhou 1
Totale 1.794
Salva come PNG Salva come JPEG
Nome #
Persistent Dystrophin Protein Restoration 90 Days after a Course of Intraperitoneally Administered Naked 2′OMePS AON and ZM2 NP-AON Complexes in mdx Mice 200
Fluorous-tag assisted synthesis of bile acid-bisphosphonate conjugates via orthogonal click reactions: an access to potential anti-resorption bone drugs 135
Rational design of nucleoside-bile acid conjugates incorporating a triazole moiety for anticancer evaluation and SAR exploration 135
Reactivity of [M=O] (3+) (M = Tc, Re) core towards 2-mercapto-1,3-azole ligands. Formation of a new organometallic complex of Re(IV) and X-ray crystal structures 130
A New Drug Delivery System Based on Tauroursodeoxycholic Acid and PEDOT 117
Conjugated Oligonucleotides for Biochemical Applications 116
Rhenium(III) and technetium(III) complexes with 2-mercapto-1,3-azole ligands and X-ray crystal structures 109
null 106
Synthesis, characterization of strontium –bile acid salts and their bioactivity vs. the anti-osteoporosis drug strontium ranelate. 98
null 98
Oligonucleotides: Current Trends and Innovative Applications in the Synthesis, Characterization, and Purification 95
Dihydroartemisinin-Bile Acid Hybridization as an Effective Approach to Enhance Dihydroartemisinin Anticancer Activity 87
Formation of threonic acid via ascorbic acid oxidative ring opening and its coordination to Pt(II). X-ray crystal structure of [Pt(threonate-O,O')(PPh3)2] 79
NEW WATER SOLUBLE COMPLEXES OF RHENIUM FOR RADIOPHARMACEUTICAL PREPARATIONS 78
NEW WATER SOLUBLE COMPLEXES OF RHENIUM 73
Antisense oligonucleotides conjugated with lipophilic compounds: synthesis and in vitro evaluation of exon skipping in duchenne muscular dystrophy 57
Polytopic carriers for platinum ions: from digalloyl depside to tannic acid 52
Bile Acid Conjugates with Anticancer Activity: Most Recent Research 52
LSD1 is an environmental stress-sensitive negative modulator of the glutamatergic synapse 50
Conjugates of oligonucleotides and bile acids and their derivatives for pharmaceutical active molecules delivery 49
UDP-GlcNAc Analogues as Inhibitors of O-GlcNAc Transferase (OGT): Spectroscopic, Computational, and Biological Studies 47
Evaluation of the Anticancer Activity of a Bile Acid-Dihydroartemisinin Hybrid Ursodeoxycholic-Dihydroartemisinin in Hepatocellular Carcinoma Cells 45
Modified nucleosides, nucleotides and nucleic acids via click azide-alkyne cycloaddition for pharmacological applications 42
Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids 37
Synthesis and exon‐skipping properties of a 3′‐ursodeoxycholic acid‐conjugated oligonucleotide targeting dmd pre‐mrna: Pre‐synthetic versus post‐ synthetic approach 34
Synthesis and in vitro cytotoxicity of deoxyadenosine-​bile acid conjugates linked with 1,​2,​3-​triazole 33
Enzymatic Synthesis of New Acetoacetate–Ursodeoxycholic Acid Hybrids as Potential Therapeutic Agents and Useful Synthetic Scaffolds as Well 28
Dihydroartemisinin-Ursodeoxycholic Bile Acid Hybrids in the Fight against SARS-CoV-2 27
In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment 26
Anticancer Activity and Molecular Mechanisms of an Ursodeoxycholic Acid Methyl Ester-Dihydroartemisinin Hybrid via a Triazole Linkage in Hepatocellular Carcinoma Cells 19
Labeling Deoxyadenosine for the Preparation of Functional Conjugated Oligonucleotides 19
Molecular Hybridization as a Strategy for Developing Artemisinin-Derived Anticancer Candidates 17
Evaluation of Anticancer Activity of Nucleoside-Nitric Oxide Photo-Donor Hybrids 13
Insights into SARS-CoV-2: Small-Molecule Hybrids for COVID-19 Treatment 1
Totale 2.304
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.662
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.662
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020241 0 0 0 0 0 43 33 40 36 34 40 15
2020/2021390 23 68 20 22 18 23 20 47 16 60 31 42
2021/2022294 24 24 20 8 13 10 27 10 13 21 23 101
2022/2023264 30 13 17 25 52 23 9 29 37 1 19 9
2023/2024171 7 18 11 10 11 21 14 10 7 8 9 45
2024/2025362 17 24 102 41 120 58 0 0 0 0 0 0
Totale 2.304